Home » Stocks » Q BioMed

Q BioMed Inc. (QBIO)

Stock Price: $1.70 USD -0.01 (-0.58%)
Updated Aug 12, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 38.60M
Revenue (ttm) 15,000
Net Income (ttm) -12.82M
Shares Out 22.71M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE 172.41
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $1.70
Previous Close $1.71
Change ($) -0.01
Change (%) -0.58%
Day's Open 1.59
Day's Range 1.59 - 1.72
Day's Volume 22,824
52-Week Range 0.34 - 3.75

More Stats

Market Cap 38.60M
Enterprise Value 35.68M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 22.71M
Float 18.96M
EPS (basic) -0.71
EPS (diluted) -0.73
FCF / Share -0.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 2.60
PE Ratio n/a
Forward PE 172.41
P/FCF Ratio n/a
PS Ratio 2,573.35
PB Ratio 330.46
Revenue 15,000
Operating Income -11.17M
Net Income -12.82M
Free Cash Flow -4.59M
Net Cash 2.92M
Net Cash / Share 0.13
Gross Margin n/a
Operating Margin -74,443.17%
Profit Margin -89,254.60%
FCF Margin -30,575.83%
ROA -323.75%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$6.00*
Low
6.00
Current: $1.70
High
6.00
Target: 6.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-8.02-9.02-12.37-6.35-0.95-0.04-
Net Income-10.28-9.27-14.54-7.17-1.09-0.04-
Shares Outstanding15.0413.7410.478.869.076.512.78
Earnings Per Share-0.68-0.67-1.39-0.81-0.12-0.01-
Operating Cash Flow-4.11-6.45-5.58-1.55-0.09-0.04-
Free Cash Flow-4.11-6.45-5.58-1.55-0.09-0.04-
Cash & Equivalents0.172.680.821.470.130.010.03
Total Debt3.692.87-2.730.30--
Net Cash / Debt-3.52-0.190.82-1.26-0.160.010.03
Assets0.643.200.831.470.130.010.03
Liabilities5.693.300.473.510.39--
Book Value-5.05-0.110.36-2.04-0.260.010.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Q BioMed Inc.
Country United States
Employees 1
CEO Denis D. Corin

Stock Information

Ticker Symbol QBIO
Stock Exchange US OTC
Unique Identifier OTCMKTS: QBIO

Description

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research for the development of novel Covid-19 therapeutics. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.